Human Metapneumovirus (HMPV): causes, symptoms, prevention, and its impact in India

Human Metapneumovirus (HMPV) has been identified as a significant cause of respiratory infections in India, particularly among children and the elderly. Studies have shown that HMPV is a common cause of acute respiratory infections (ARIS) in Indian children, with a prevalence rate of up to 15% in some regions.

In India, HMPV infections have been reported throughout the year, with a peak incidence during the winter months. The virus has been detected in various parts of the country, including urban and rural areas. The impact of HMPV in India is significant, with the virus causing a substantial burden of disease, particularly among vulnerable populations such as young children, the elderly, and those with underlying health conditions. HMPV infections can lead to severe respiratory illness, including pneumonia, bronchiolitis, and acute respiratory distress syndrome (ARDS), which can be life-threatening if not treated promptly and effectively.

Efforts to prevent and control HMPV infections in India are crucial to reduce the burden of disease and prevent severe illness. This can be achieved through improved hygiene practices, such as frequent handwashing, avoiding close contact with infected individuals, and staying home when symptoms appear.

Common symptoms

The symptoms of HMPV are often mistaken for other respiratory illnesses, especially in a setting where transmission is common, including:

• Fever
• Cough
• Runny or stuffy nose
• Sore throat
• Mild wheezing

Severe symptoms

In vulnerable groups, HMPV is known to be a significant risk, leading to severe acute respiratory infections such as:

• Shortness of breath
• Bronchiolitis
• Pneumonia
• Exacerbation of chronic conditions like asthma or chronic obstructive pulmonary disease (COPD)

While the flu often causes systemic symptoms like muscle aches and chills, HMPV symptoms are more localized to the respiratory system.

HMPV spreads in ways similar to other respiratory viruses, detailing aspects of the transmission of the virus. Similar to respiratory syncytial virus, HMPV spreads through droplets from sneezes, coughs, and talking:

1. Droplet transmission: through sneezes, coughs, and talking.

2. Direct contact: shaking hands or touching infected individuals.

3. Contaminated surfaces: the virus can survive on surfaces like doorknobs, toys, and phones for hours.

a. Peak period: winter months (November to February).

b. Impact of pollution: poor air quality during winter exacerbates respiratory illnesses, including HMPV.

Diagnosing HMPV, a common cause of acute respiratory infections, requires clinical evaluation and laboratory tests:

• Polymerase chain reaction (PCR): the most reliable diagnostic tool for detecting HMPV.

• Antigen testing: a quicker but less sensitive alternative.

• Imaging tests: chest x-rays or CT scans in severe cases to check for complications like pneumonia.

• Restricted availability of advanced diagnostic tools in rural regions.
• A lack of awareness among healthcare providers and patients alike.

Supportive care

As there are no specific antiviral treatments for HMPV, care focuses on alleviating symptoms:

• Fever management: paracetamol for fever and body aches.
• Hydration: maintaining proper fluid levels to stay hydrated and prevent dehydration.
• Respiratory support: oxygen therapy for severe breathing issues.

Hospitalization

Patients with severe symptoms, such as pneumonia or bronchiolitis, may require hospitalization for: patients with severe symptoms, such as pneumonia or acute respiratory distress syndrome, may require hospitalization for:

• Intravenous (iv) fluids
• Corticosteroids to reduce inflammation.
• Ventilatory support in critical cases.

Antibiotics

Antibiotics cannot treat HMPV since it is a viral infection. However, they may be prescribed if a secondary bacterial infection develops.

Prevention and control measures for human Metapneumovirus (HMPV) are crucial to reduce the spread of the virus and prevent severe illness. Here are some effective measures to prevent and control HMPV:

• Hand hygiene: regularly washing your hands with soap and water is crucial for preventing the spread of HMPV. When soap and water aren’t accessible, using hand sanitizer is an effective alternative.

• Avoid close contact: avoid close contact with individuals who are infected with HMPV, especially those who are experiencing symptoms such as coughing and sneezing.

• Stay home: stay home when symptoms appear, and avoid going to work or school to prevent the spread of the virus.

• Cover mouth and nose: cover the mouth and nose with a tissue when coughing or sneezing, and dispose of the tissue properly.

• Clean and disinfect: clean and disinfect surfaces and objects that may be contaminated with the virus, such as doorknobs, light switches, and countertops.

• Vaccination: while there is no specific vaccine available for HMPV, vaccination against other respiratory viruses such as influenza and RSV can help prevent co-infections and reduce the severity of illness.

• Improved ventilation: improve ventilation in homes, schools, and workplaces to reduce the concentration of airborne viruses.

• Personal protective equipment: use personal protective equipment (PPE) such as masks, gloves, and gowns when caring for individuals with HMPV infection.

By implementing these prevention and control measures, we can reduce the spread of HMPV and prevent severe illness, particularly among vulnerable populations.

1. Public education campaigns in local languages to raise awareness.

2. Enhanced sanitation facilities and improved access to clean water in rural communities.

HMPV complications are more likely in high-risk groups and may include acute respiratory distress syndrome, which can be life-threatening.

HMPV complications are more likely in high-risk groups and may include:

• Bronchiolitis: a condition characterized by inflammation of the small airways in the lungs.
• Pneumonia: particularly dangerous for the elderly and those with weakened immune systems.
• Asthma and COPD flare-ups: increased risk of hospitalization.

• Children: more likely to develop severe symptoms like bronchiolitis.

• Adults: symptoms are milder but can lead to complications in those with pre-existing conditions.

While both are respiratory viruses, they differ significantly:

The Covid-19 pandemic brought respiratory viruses into the spotlight, leading to:

• Improved hygiene practices: regular mask usage and hand hygiene.
• Better diagnostic tools: increased availability of PCR testing.
• Reduced transmission: lockdowns and social distancing inadvertently lowered HMPV cases.

Yes, human Metapneumovirus (HMPV) is a significant public health concern. HMPV is a common cause of respiratory infections, particularly in high-risk groups such as older adults, young children, and immunocompromised individuals. Severe HMPV infection can lead to serious complications, such as pneumonia, bronchiolitis, and respiratory failure, which can be life-threatening.

HMPV outbreaks have been reported in various settings, including hospitals, long-term care facilities, and schools. These outbreaks can have a significant impact on public health, particularly in high-risk populations. The virus can spread rapidly in these environments, leading to increased morbidity and mortality rates.

Furthermore, HMPV is a significant concern in healthcare settings, where it can spread quickly among patients and healthcare workers. This may result in higher rates of illness and death, as well as rising healthcare expenses. The burden on healthcare systems can be substantial, particularly during peak seasons when other respiratory viruses are also prevalent.

Overall, HMPV is a significant public health concern that requires attention and action to prevent and control its spread. This includes promoting awareness, improving diagnostic capabilities, and developing effective prevention and treatment strategies. By addressing these areas, we can better protect vulnerable populations and reduce the overall impact of HMPV on public health.

Global initiatives

• Development of vaccines and antiviral drugs.
• Enhanced surveillance systems for respiratory viruses.

India’s role

India’s robust pharmaceutical and research sectors can play a significant role in HMPV research, particularly in vaccine development.

1. Is HMPV as dangerous as covid-19?

No, HMPV is generally less severe but can be dangerous for children, the elderly, and those with weakened immune systems.

2. How can I differentiate HMPV from the flu?

While both share symptoms, HMPV focuses on respiratory issues, whereas the flu often includes body aches and chills.

3. Can HMPV and Covid-19 co-infections occur?

Yes, individuals can contract both viruses simultaneously, potentially worsening symptoms.

4. Is there a vaccine for HMPV?

Currently, there is no vaccine for HMPV, but research is ongoing.

5. How long does HMPV last?

Symptoms usually last 5-10 days, with more severe cases requiring longer recovery.

6. What should I do if I suspect HMPV?

Consult a healthcare provider for proper diagnosis and supportive care.

Conclusion

HMPV is a common but often overlooked respiratory virus that poses significant risks to vulnerable populations, especially in densely populated regions like India. While it shares similarities with the flu and Covid-19, its unique characteristics require targeted awareness and prevention strategies. Continued research, improved diagnostic tools, and public health initiatives can help mitigate its impact.

The content provided in this blog is for informational purposes only and should not be considered as medical, legal, or professional advice. Every effort has been taken to guarantee the accuracy of the information provided. Information presented, we do not guarantee its completeness, accuracy, or applicability to individual circumstances.

ARN: Zuno/Blog/DM/Human Metapneumovirus (HMPV): causes, symptoms, prevention, and its impact in India/01/25/14

All Rights Reserved.